Background
Methods
Databases searched | Disease search terms | Economic, humanistic and societal burden search terms |
---|---|---|
• Medline
| “Herpes Zoster” OR “Shingles” OR “Post-herpetic Neuralgia” OR “Post herpetic Neuralgia” OR “Postherpetic Neuralgia” OR “PHN” | “Burden” OR “Humanistic” OR “quality of life” OR “QOL” OR “HRQOL” OR “cost” OR “economic” OR “resource” OR “society” OR “societal” OR “family” OR “relatives” OR “Caregiver” OR “care$” OR “activities of daily living” OR “ADLS” OR “daily activities” OR “cost of illness” OR “autonomy” OR “hospitalisation” OR “hospitalization” |
• Embase
| ||
• PscyINFO
| ||
• EconLit.
| ||
• Health Economic Evaluations Database (HEED)
| ||
• Centre for Reviews and Dissemination databases:
| ||
- Database of Abstracts of Reviews of Effects (DARE), | ||
- Health Technology Assessment (HTA) | ||
- NHS Economic Evaluation Database (NHS EED) |
Inclusion criteria | Exclusion criteria | |
---|---|---|
Country setting
|
Present data from a country in the EU or EU in general
|
Only present data from a non-EU country. No data specific to the EU.
|
Population
|
Adults with HZ or PHN
|
Children
|
Focus mainly on chicken pox
| ||
Immunodepressed patients only (e.g. HIV patients) | ||
Studies that contain information on key search terms (inc. QoL, burden, productivity)
|
Studies that do NOT contain information on key search terms
| |
Study design
|
Real world data, observational studies, effectiveness, qualitative research and cost studies
|
Clinical trials of efficacy and safety of treatments presenting QoL data as secondary endpoint only
|
Clinical trials of Zostavax
| ||
Focus mainly on epidemiological evidence (e.g. incidence, prevalence etc.) | ||
Publication type
|
For conference abstracts, exclusion if manuscript corresponding to this abstract and presenting equivalent information is already published
|
Results
Search results
Overview of selected articles
Author and year | Country perspective | Population | Healthcare utilisation | Economic data | HRQoL | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|
HZ | HZ and PHN | PHN1 | PHN3 | PHN Other/Undefined | Direct costs | Indirect costs | Total costs | ||||
Annemans et al. (2010) [26] | Belgium | ✓ | X | ✓ | ✓ | X | ✓ | ✓ | ✓ | ✓ | X |
Bayas et al. (2011) [37] | Spain Catalonia | X | ✓ | X | X | X | ✓ | ✓ | X | X | X |
Berrut, G. and C. Baptiste (2013) [38] | France | ✓ | X | X | X | X | ✓ | X | X | X | X |
Blein, C., et al. (2013) [39] | France | ✓ | X | X | X | X | ✓ | X | X | X | X |
Bilcke et al. (2012) [40] | Belgium | X | ✓ | X | ✓ | X | ✓ | ✓ | ✓ | X | X |
Bouhassira et al. (2012) [15] | France | ✓ | ✓ | X | ✓ | X | X | X | X | X | ✓ |
Bresse, X., et al. (2013) [41] | France | ✓ | X | X | ✓ | X | ✓ | X | X | X | X |
Bricout, H., et al. (2013) [42] | Italy | ✓ | X | X | X | X | X | X | ✓ | X | ✓ |
Bricout, H., et al. (2013) [42] | Italy | ✓ | X | X | ✓ | X | ✓ | X | X | X | ✓ |
Brisson et al. (2003) [43] | England & Wales | X | ✓ | X | X | ✓ | ✓ | ✓ | ✓ | ✓ | X |
Castro-Lopes, J. M., et al. (2013) [44] | Portugal | X | X | X | X | ✓ | ✓ | X | X | X | ✓ |
Cebrian-Cuenca et al. (2011) [27] | Spain, Valencia | ✓ | X | ✓ | ✓ | X | ✓ | ✓ | ✓ | ✓ | X |
Chidiac et al. (2001) [21] | France | ✓ | ✓ | X | X | ✓ | ✓ | X | X | X | ✓ |
De Juanes et al. (2011) [45] | Spain Madrid | X | ✓ | X | X | ✓ | ✓ | ✓ | X | X | X |
Di Legami et al. (2007) [46] | Italy – Piemonte | ✓ | X | X | X | ✓ | ✓ | ✓ | X | X | X |
Edmunds et al. (2001) [47] | England and Wales | X | ✓ | ✓ | X | X | ✓ | ✓ | X | X | X |
Franco, E., et al. (2013) [48] | Italy | ✓ | X | X | ✓ | X | ✓ | X | X | X | ✓ |
Garcia-Doval et al. (2010) [49] | Spain | ✓ | X | X | X | ✓ | ✓ | X | X | X | X |
Gater, A., et al. (2014) [50] | UK | ✓ | X | X | X | X | ✓ | X | X | X | ✓ |
Gauthier et al. (2009) [28] | UK | ✓ | X | ✓ | ✓ | X | ✓ | ✓ | X | X | ✓ |
Gialloreti et al. (2010) [29] | Italy | ✓ | X | ✓ | ✓ | X | ✓ | ✓ | ✓ | ✓ | X |
Gil et al. (2004) [51] | Spain | ✓ | X | X | X | X | ✓ | ✓ | X | X | X |
Gil et al. (2009) [52] | Spain | ✓ | X | X | X | X | ✓ | ✓ | X | X | X |
Gil-Prieto et al. (2011) [53] | Spain | ✓ | X | X | X | X | ✓ | ✓ | X | X | X |
Gil-Prieto, R., et al. (2014) [54] | Spain | ✓ | X | X | X | X | ✓ | X | X | X | X |
Gonzalez et al. (2010) [55] | France | ✓ | X | X | X | X | ✓ | X | X | X | X |
Lionis et al. (2011) [56] | Greece | ✓ | X | ✓ | X | X | X | X | X | X | ✓ |
Loncar, Z., et al. (2013) [57] | Croatia | ✓ | X | X | X | X | ✓ | X | X | X | ✓ |
Lukas et al. (2012) [58] | Germany, Spain, Portugal, the Netherlands, Belgium, Sweden and Switzerland | ✓ | ✓ | X | ✓ | X | X | X | ✓ | X | ✓ |
Mesquita, M. and F. Froes (2013) [59] | Portugal | ✓ | X | X | X | X | ✓ | X | X | X | X |
Mick et al. (2010) [30] | France | X | ✓ | X | ✓ | X | ✓ | ✓ | ✓ | ✓ | X |
Moore et al. (2010) [60] | UK | X | ✓ | ✓ | ✓ | X | X | X | ✓ | X | X |
Morant-Talamante, N., et al. (2013) [61] | Spain | ✓ | X | X | X | X | ✓ | X | X | X | X |
Mordarski et al. (2009) [62] | Poland | X | X | X | X | ✓ | X | X | X | X | ✓ |
Nilsson, J., et al. (2013) [63] | Sweden | X | ✓ | X | X | X | X | X | ✓ | ✓ | X |
Pierik et al. (2012) [64] | Holland/the Netherlands | ✓ | X | X | X | X | ✓ | X | X | X | X |
Rabaud, C., et al. (2013) [65] | France | ✓ | X | ✓ | ✓ | X | ✓ | X | X | X | ✓ |
Rehm et al. (2010) [66] | 14 European countries (countries not specified) | X | X | ✓ | X | X | X | X | X | X | ✓ |
Schiffner-Rohe et al. (2011) [67] | Germany | ✓ | X | ✓ | X | X | ✓ | ✓ | X | ✓ | X |
Scott et al. (2003) [68] | UK | ✓ | X | X | ✓ | X | X | X | X | X | ✓ |
Scott et al. (2006) [7] | UK | X | ✓ | X | ✓ | X | X | X | ✓ | ✓ | ✓ |
Serpell, M., et al. (2014) [14] | UK | X | X | X | ✓ | X | ✓ | X | X | X | ✓ |
Sicras-Mainar et al. (2012) [69] | Spain | ✓ | ✓ | X | X | ✓ | ✓ | ✓ | ✓ | ✓ | X |
Souliotis, K., et al. (2013) [70] | Greece | X | ✓ | X | X | X | X | ✓ | ✓ | X | X |
Studahl, M., et al. (2013) [71] | Sweden | ✓ | X | X | X | X | ✓ | X | X | X | X |
Szucs (2011) [72] | Switzerland | ✓ | X | X | ✓ | ✓ | X | ✓ | ✓ | ✓ | X |
Ultsch et al. (2011) [73] | Germany | ✓ | X | X | ✓ | X | ✓ | X | X | X | X |
Ultsch et al. (2012) [31] | Germany | ✓ | X | X | ✓ | X | ✓ | ✓ | ✓ | ✓ | X |
Van Hoek et al. (2009) [74] | England and Wales | ✓ | X | X | ✓ | X | ✓ | ✓ | X | X | X |
Van Seventer et al. (2006) [25] | France, Germany, Italy, Netherlands, Spain, UK | X | X | X | ✓ | X | ✓ | X | X | X | ✓ |
Volpi et al. (2007) [75] | Italy | ✓ | X | X | X | X | X | X | X | X | ✓ |
Volpi et al. (2008) [76] | Italy | ✓ | ✓ | X | ✓ | ✓ | X | X | X | X | ✓ |
Weinke et al. (2010) [77] | Germany | ✓ | X | X | ✓ | X | X | X | ✓ | X | ✓ |
Healthcare utilisation
Medical visits
Hospitalisations
Medication use
Diagnostic/laboratory procedures
Direct costs of management
Outpatient costs
Hospitalisation and inpatient costs
Country | HZ/PHN | HZ (without PHN) | PHN |
---|---|---|---|
Belgium [40] | - | €5,982 (€798-31,689) | - |
(all ages) | |||
France [41] | - | €2,774.28 (50+years) | €3,731.09 (50+years) |
Germany [31] | - | €4,189.74 (50+years) | €4,279.68 (50+years) |
€3,282.64 (all ages) | €4,112.03 (all ages) | ||
Italy [29] | - | €3,188.16 ± €1,614.99 (50+years) | €3,451.38 ± €3,248.43 (50+years) |
€3,366.4 -4,505.6 | €5,019.84 (aged 40–49) | €5,108.04 (aged 50–59) | |
(all ages) | €4,495.68 – 5,139.54 (aged 50–59) | €4,732.56 (aged 60–69) | |
€4,210.92 – 4,782.96 (aged 60–69) | €4,478.04 (70+) | ||
€4,062.24 – 4,556.16 (aged 70+) |
Indirect costs
Total costs of management
Country | Population age | Cost per case | ||
---|---|---|---|---|
HZ | PHN1* | PHN3^ | ||
Belgium [26] | Aged ≥50 | €118 (no pain) | €156.94 (mild pain) | €329.22 (mild pain) |
€1,150.50 (severe pain) | €1,085.60 (severe pain) | €2,037.86 (severe pain) | ||
France [30] | Aged ≥50 | €419.87 (271–586) | €672.76 (451–968) | - |
Germany [31] | Aged ≥50 | €388.30 (354–425) | - | €1,427.80 (1,002-1,917) |
Germany [67] | Aged ≥50 | €729.57 | € 2,167.89 | |
Italy [29] | Aged ≥50 | €888.06 | - | €1,66.65 |
Spain [27] | Aged >14 | Overall: €446.04 (SD 508.58) | €647.82 (SD 684.4) | €968.78 (SD 803.58) |
50-59: €282.06 (SD 273.15) | ||||
60-69:€510.52 (SD 512.73) | ||||
>70: €422.91 (SD 388.66) | ||||
Spain [69] | Aged >30 | €460.95 | €1,956.15 | - |
Sweden [63] | All ages | €902.88 (HZ and PHN) | ||
Switzerland [72] | Aged ≥50 | €394.46 (no pain) | - | €381.15 (no pain) |
€1,835.57 (severe pain) | €2,442.99 (severe pain) | |||
UK [7] | Not specified | €793.60 (31–6,394) | - | - |
(all ages) | Aged +65: €788.48 |
Humanistic burden and impact on quality of life
Pain and interference with daily activities
Health state domains | HZ (mean scores) | PHN (mean scores) |
---|---|---|
General activity
| 3.8-4.4 | 3.1-5.7 |
Mood
| 3.4-4.5 | 3.4-5.9 |
Walking ability
| 1.7-4.0 | 1.7-5.8 |
Normal work
| 3.3-4.4 | 2.9-6.1 |
Social relations
| 2.1-3.5 | 2.1-5.4 |
Sleep
| 4.5-4.9 | 6.3-6.5 |
Enjoyment of life
| 3.6-4.0 | 3.8-5.2 |